Select Language
HLA-A*0301 & B2M & gp100 (ALLAVGATK)
Product Inquiry
HLA-A*0301 & B2M & gp100 (ALLAVGATK) Background
Glycoprotein 100, is also well known as gp100 and Melanocyte protein PMEL. This antigen is a melanocyte-specific type I transmembrane glycoprotein and composed of 661 amino acids. Glycoprotein 100 is related to the tumor regression in metastatic melanoma patients after adoptive therapy, by which its epitopes being recognized by tumor lymphocytes and T-cells. The gp100280–288(YLEPGPVTA) was originally shown to be recognized by HLA-A*0301 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR -T studies. The Human HLA-A*0301 gp100 (YLEPGPVTA) complex protein is a complex of HLA-A*0301 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100.
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| PRT-001 | PRT-001 | Phase 3 Clinical | Particle Therapeutics | Hypoglycemia | Details |
| Retatrutide | LY-3437943 | Phase 3 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Atherosclerosis; Renal Insufficiency; Sleep Apnea, Obstructive; Hepatic Insufficiency; Osteoarthritis, Knee; Cardiovascular Diseases; Renal Insufficiency, Chronic; Obesity; Overweight | Details |
| Survodutide | BI-456906; BI-456909 | Phase 3 Clinical | Zealand Pharma A/S | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Renal Insufficiency; Liver Cirrhosis; Fibrosis; Hepatitis; Liver Diseases; Obesity; Overweight; Diabetes Mellitus | Details |
| Pemvidutide | ALT-801(Altimmune); SP-1373; VPD-107 | Phase 2 Clinical | Velocity Pharmaceutical Development | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| Efinopegdutide | JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Liver Diseases; Hepatic Insufficiency; Obesity; Kidney Failure, Chronic | Details |
| Efocipegtrutide | HM-15211 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| volagidemab | AMG-477; REMD-477 | Phase 2 Clinical | Amgen Inc | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin Resistance; Hyperglycemia; Diabetes Mellitus | Details |
| Isosteviol | ISV; STX-03 | Phase 2 Clinical | Stevia Pharma | Diabetes Mellitus, Type 2 | Details |
| Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) | Phase 2 Clinical | Pharmsynthez, Xenetic Biosciences Inc | Diabetes Mellitus, Type 2; Obesity | Details | |
| Pegapamodutide | WG4ID2U7FT; TT-401; LY-2944876; OPK-88003 | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Obesity | Details |
| IONIS-GCGRRx | IONIS-GCGRRx; ISIS-449884; ISISGCGRRx | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Diabetes Mellitus, Type 2 | Details |
| Efpegerglucagon | HM-15136 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Congenital Hyperinsulinism; Diabetes Mellitus, Type 2 | Details |
| AZD9550 | AZD9550; AZD-9550 | Phase 2 Clinical | Astrazeneca Plc | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| MWN-101 | MWN-101 | Phase 2 Clinical | Shanghai Minwei Biotechnology Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| RBD-4988 | RBD-4988 | Phase 2 Clinical | Suzhou Ribo Life Science Co Ltd | Diabetes Mellitus, Type 2 | Details |
| PB-718 | PB-718 | Phase 2 Clinical | Peg Bio Co Ltd | Congenital Hyperinsulinism; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| DD-01 | DD-01 | Phase 2 Clinical | D&D Pharmatech | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| Cotadutide | MEDI-0382 | Phase 2 Clinical | Medimmune Llc | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Renal Insufficiency; Liver Cirrhosis; Hepatic Insufficiency; Diabetic Nephropathies; Renal Insufficiency, Chronic; Obesity; Diabetes Mellitus | Details |
| NN-9277 | NN-9277; NNC-9204-1177 | Phase 1 Clinical | Novo Nordisk A/S | Obesity; Overweight; Nutritional and Metabolic Diseases | Details |
| Glucagon (rDNA origin, Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity | Details | |
| Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) | Phase 1 Clinical | Translational Research Institute For Metabolism And Diabetes | Obesity | Details | |
| NNC-92041706 | NNC9204-1706; NNC-92041706; NN-9423; NNC-92041706-A | Phase 1 Clinical | Novo Nordisk A/S | Obesity; Nutritional and Metabolic Diseases | Details |
| PRT-003 | PRT-003 | Phase 1 Clinical | Particle Therapeutics | Details | |
| SAR-441255 | SAR-441255 | Phase 1 Clinical | Sanofi | Overweight | Details |
| Glucagon/insulin human(Abvance Therapeutics) | ABV-100 | Phase 1 Clinical | Abvance Therapeutics | Hypoglycemia | Details |
| PB-722 | PB722; PB-722 | Phase 1 Clinical | Peg Bio Co Ltd | Congenital Hyperinsulinism | Details |
| UBT-251 | UBT-251; UBT251 | Phase 1 Clinical | Lianbang Biotechnology (Zhuhai Hengqin) Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| TY-751 | TY-751; TY751 | Phase 1 Clinical | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Diabetes Mellitus | Details | |
| DA-1726 | DA-1726 | Phase 1 Clinical | Dong-A ST Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| ZX-2021 | ZX2021; ZX-2021 | Phase 1 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| DR-10624 | DR-10624 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Hypertriglyceridemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity; Overweight; Diabetes Mellitus | Details |
| TB-001 | TB-001; TB001 | Phase 1 Clinical | Shenzhen Tuwei Anchuang Technology Development Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis | Details |
| Human glucagon(Shanghai Duomirui) | Phase 1 Clinical | Shanghai Duomirui Biotechnology Co Ltd | Hypoglycemia | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucagon (rDNA origin, Novo Nordisk) | GL-G | Approved | Novo Nordisk A/S | GlucaGen, Glucagon G | United States | Gastrointestinal Diseases; Hypoglycemia | Novo Nordisk A/S | 1998-06-22 | Diabetes Mellitus, Type 1; Gastrointestinal Diseases; Hypoglycemia; Obesity | Details |
| Dasiglucagon | ZP-GA-1; ZP-4207 | Approved | Zealand Pharma A/S | Zegalogue | United States | Hypoglycemia | Zealand Pharma Us Inc | 2021-03-22 | Diabetes Mellitus, Type 1; Congenital Hyperinsulinism; Hypoglycemia; Glucose Metabolism Disorders; Hyperinsulinism | Details |
| Glucagon | MP-123456B | Approved | Eli Lilly And Company | Ogluo, Baqsimi | EU | Hypoglycemia | Eli Lilly Nederland BV | 1960-11-14 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia | Details |
| Glucagon intranasal (Eli Lilly/Locemia Solutions) | AMG504-1; LY-900018 | Approved | Amg Medical, Locemia Solutions | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details | |||||
| Glucagon (Xeris Pharmaceuticals) | Approved | Xeris Pharmaceuticals Inc | Gvoke | United States | Hypoglycemia | null | 1960-01-01 | Hypoglycemia; Hyperinsulinism | Details |
- Product Inquiry
- Marketed Drug Information
- Clinical Drug Information
Share to: